Identification of the antigens predominantly reacted with serum from patients with hepatocellular carcinoma
Identification of the antigens predominantly reacted with serum from patients with hepatocellular carcinoma
复制标题
DOI：
10.1002/cncr.11374
复制
发表时间：
2003-05-15
期刊：
影响因子：
6.2
通讯作者：
Shiratori, Y
中科院分区：
文献类型：
--
作者：
Uemura, M;Nouso, K;Shiratori, Y
背景资料。为鉴定肝细胞癌患者免疫监测系统特异性识别的抗原，采用重组基因表达文库的血清学分析方法，对两个中分化肝细胞癌的互补DNA文库进行筛选，并测定克隆序列。为了研究这些抗原的免疫反应性，对20例肝细胞癌患者、20例健康志愿者和16例慢性病毒性肝炎患者的血清进行了检测。它们包括SART1、p57Kip2、ROCK-1、γ-连环蛋白和热休克蛋白，它们被归类为肿瘤相关基因。27个抗原中有3个抗原--TBP-1(TBP-1)、β4整合素结合蛋白(p27[BBP])和核糖体蛋白L30(RpL30)--主要与肝细胞癌患者血清反应(分别为55%、45%和20%)。对照组患者未检测到这三种抗原的抗体。结论：抗TBP-1、p27(BBP)和rpL30的肿瘤特异性体液免疫反应可在肝细胞癌患者体内产生，这些抗体也可作为肿瘤标志物。(C)2003年美国癌症协会。
BACKGROUND. To identify antigens specifically recognized by the immune surveillance system in patients with hepatocellular carcinoma (HCC), the authors examined two complementary DNA (cDNA) libraries of moderately differentiated HCC by serologic analysis of recombinant cDNA expression libraries (SEREX).METHODS. The libraries were screened with autologous patients' sera, and sequences of the reacted clones were determined. To study the immunoreactivity of the antigens, sera from 20 patients with HCC, from 20 healthy volunteers, and from 16 patients with chronic viral hepatitis were examined.RESULTS. Twenty-seven antigens were identified. They included SART1, p57Kip2, ROCK-1, gamma-catenin, and heat shock proteins, which are classified as tumor-associated genes. Three of 27 antigens-Tat-binding protein-1 (TBP-1), beta4 integrin-binding protein (p27[BBP]), and ribosomal protein L30 (rpL30)-were reacted predominantly with sera from patients with HCC (55% of patients, 45% of patients, and 20% of patients, respectively). Patients in the control group had no antibodies against these three antigens. Seventy percent of patients with HCC had the antibody against at least one of these antigens.CONCLUSIONS. Disease specific humoral immune response against TBP-1, p27(BBP), and rpL30 was induced in patients with HCC, and the antibodies against these antigens also may be used as tumor markers. (C) 2003 American Cancer Society.